Premenstrual syndrome, neuroactive steroids and the brain

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th edition. U.S. Department of Health and Human Services, Washington, DC 1994; 714–18
   Google Scholar
• Hurt S W, Schnurr P P, Severino S K, et al. Late luteal phase dysphoric disorder in 670 women evaluated for premenstrual complaints. Am J Psychiatry 1992; 149: 525–30
   PubMed Web of Science ®Google Scholar
• Hammarbäck S, Bäckström T, MacGibbon-Taylor B. Diagnosis of premenstrual tension syndrome: description and evaluation of a procedure for diagnosis and differential diagnosis. J Psychosom Obstet Gynaecol 1989; 10: 25–42
   Web of Science ®Google Scholar
• Ekholm U B, Bäckström T. Influence of premenstrual syndrome on family, social life, and work performance. Health Services 1994; 24: 629–47
   Google Scholar
• Andersch B, Wendestam C, Hahn L, et al. Premenstrual complaints. I. Prevalence of premenstrual symptoms in a Swedish urban population. J Psychosom Obstet Gynaecol 1986; 5: 39–49
   Google Scholar
• Rivera-Tovar A D, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990; 147: 1634–6
   PubMed Web of Science ®Google Scholar
• Endicott J, Halbreich U. Clinical significance of premenstrual dysphoric changes. J Clin Psychiatry 1988; 49: 486–9
   PubMed Web of Science ®Google Scholar
• Hammarbäck S, Bäckström T. A demographic study in subgroups of women seeking help for premenstrual syndrome. Acta Obstet Gynecol Scand 1989; 68: 247–53
   PubMed Web of Science ®Google Scholar
• Pearlstein T B, Frank E, Rivera-Tovar A, et al. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord 1990; 20: 129–34
   PubMed Web of Science ®Google Scholar
• Steege J F, Stout A L, Knight D L, et al. Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome. Am J Obstet Gynecol 1992; 167: 168–72
   PubMed Web of Science ®Google Scholar
• Fava M. Comorbid anxiety and depression among patients with late luteal phase dysphoric disorder. J Anxiety Disord 1992; 6: 325–35
   Web of Science ®Google Scholar
• Graze K K, Nee J, Endicott J. Premenstrual depression predicts future major depressive disorder. Acta Psychiatr Scand 1990; 81: 201–5
   PubMed Web of Science ®Google Scholar
• Ashby C R, Carr L A, Cool C L, et al. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol Psychiatry 1988; 24: 225–33
   PubMed Web of Science ®Google Scholar
• Ashby C R, Carr L A, Cook C L, et al. Alteration of 5-HT uptake by plasma fractions in the premenstrual syndrome. J Neural Transm 1990; 79: 41–50
   PubMed Web of Science ®Google Scholar
• Caldecot-Hazard S, Morgan D G, DeLeon-Jones F, et al. Clinical and biochemical aspects of depressive disorder: II. Transmitter/receptor theories. Synapse 1991; 9: 251–301
   PubMed Web of Science ®Google Scholar
• Rojansky N, Halbreich U, Zander K, et al. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest 1991; 31: 146–52
   PubMed Web of Science ®Google Scholar
• Halbreich U, Petty F, Yonkers K, et al. Low plasma γ-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry 1996; 153: 718–20
   PubMed Web of Science ®Google Scholar
• Parry B L, Mendelson W B, Duncan W C, et al. Longitudinal sleep EEG, temperature, and activity measurements across the menstrual cycle in patients with premenstrual depression and in age-matched controls. Psychiatry Res 1989; 30: 285–303
   PubMed Web of Science ®Google Scholar
• Severino S. Late luteal phase dysphoric disorder: a scientific puzzle. Med Hypotheses 1993; 41: 229–34
   PubMed Web of Science ®Google Scholar
• Steiner M, Steinberg S, Stewart S, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995; 332: 1529–34
   PubMed Web of Science ®Google Scholar
• Yonkers K A, White K. Premenstrual exacerbation of depression: one process or two?. J Clin Psychiatry 1992; 53: 289–92
   PubMed Web of Science ®Google Scholar
• Endicott J. The menstrual cycle and mood disorders. J Affect Disord 1993; 29: 193–200
   PubMed Web of Science ®Google Scholar
• Glass G S, Heninger G R, Lansky M, et al. Psychiatric emergency related to the menstrual cycle. Am J Psychiatry 1971; 128: 705–11
   PubMed Web of Science ®Google Scholar
• Abramowitz E S, Baker A H, Fleischer S F. Onset of depressive psychiatric crises and the menstrual cycle. Am J Psychiatry 1982; 139: 475–8
   PubMed Web of Science ®Google Scholar
• Tonks C M, Rack P H, Rose M J. Attempted suicide and the menstrual cycle. J Psychosom Res 1968; 11: 319–23
   PubMed Web of Science ®Google Scholar
• Pallis D J, Holding T A. The menstrual cycle and suicidal intent. J Biosoc Sci 1976; 8: 27–33
   PubMed Web of Science ®Google Scholar
• Fourestié V, Lignières B, Roudot-Thoraval F, et al. Suicide attempts in hypo-estrogenic phases of the menstrual cycle. Lancet 1986; 2: 1357–60
   PubMed Web of Science ®Google Scholar
• Liebowitz M R, Fyer A J, Gorman J M, et al. Lactate provocation of panic attacks. Arch Gen Psychiatry 1984; 41: 764–70
   PubMed Web of Science ®Google Scholar
• Harrison W M, Sandberg D, Gorman J M, et al. Provocation of panic with carbon dioxide inhalation in patients with premenstrual dysphoria. Psychiatry Res 1989; 27: 183–92
   PubMed Web of Science ®Google Scholar
• Johnson M R, Lydiard R B, Ballenger J C. Panic disorder. Pathophysiology and drug treatment. Drags 1995; 49: 328–44
   Google Scholar
• Sandberg D, Endicott J, Harrison W, et al. Sodium lactate infusion in late luteal phase dysphoric disorder. Psychiatry Res 1996; 46: 79–88
   Google Scholar
• McLeod D R, Hoehn-Saric R, Foster G V, et al. The influence of premenstrual syndrome on ratings of anxiety in women with generalized anxiety disorder. Acta Psychiatr Scand 1993; 88: 248–51
   PubMed Web of Science ®Google Scholar
• Cameron O G, Kuttesch D, McPhee K, et al. Menstrual fluctuation the symptoms of panic anxiety. J Affect Disord 1988; 15: 169–74
   PubMed Web of Science ®Google Scholar
• Cook B L, Noyes R, Garvey M J, et al. Anxiety and the menstrual cycle in panic disorder. J Affect Disord 1990; 19: 221–6
   PubMed Web of Science ®Google Scholar
• Kaspi S P, Otto M W, Pollack M H, et al. Premenstrual exacerbation of symptoms in women with panic disorder. J Anxiety Disord 1994; 8: 131–8
   Web of Science ®Google Scholar
• George D T, Ladenheim J A, Nutt D J. Effect of pregnancy on panic attacks. Am J Psychiatry 1987; 144: 1078–9
   PubMed Web of Science ®Google Scholar
• Corney R H, Stanton R. A survey of 658 women who report symptoms of premenstrual syndrome. J Psychosom Res 1991; 35: 471–82
   PubMed Web of Science ®Google Scholar
• Frank R T. The hormonal causes of premenstrual tension. Arch Neurol Psychiatry 1931; 26: 1053–7
   Google Scholar
• DeVane C W. Editorial: premenstrual syndrome. J Clin Endocrinol Metab 1991; 71: 250–1
   Google Scholar
• Hammarbäck S, Ekholm U B, Bäckström T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol (Copenh) 1991; 125: 132–7
   PubMedGoogle Scholar
• Hammarbäck S, Bäckström T. Induced anovulation as treatment of premenstrual tension syndrome. Acta Obstet Gynecol Scand 1988; 67: 159–66
   PubMed Web of Science ®Google Scholar
• Brown C S, Ling F W, Andersen R N, et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994; 84: 779–86
   PubMed Web of Science ®Google Scholar
• Mezrow G, Lobo R, Shoupe D, et al. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 1994; 62: 932–7
   PubMed Web of Science ®Google Scholar
• Mortola J F, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1999; 71: 252A–252F
   Google Scholar
• Studd J, Leather A T. The need for add-back with a gonadotropin-releasing hormone agonist therapy. Br J Obstet Gynaecol 1996; 103: 1–4
   PubMedGoogle Scholar
• Bäckström T, Sanders D, Leask R, et al. Mood, sexuality, hormones, and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom Med 1983; 45: 503–7
   PubMed Web of Science ®Google Scholar
• Halbreich U, Endicott J, Goldstein S, et al. Premenstrual changes and changes in gonadal hormones. Acta Psychiatr Scand 1986; 74: 576–86
   PubMed Web of Science ®Google Scholar
• Redei E, Freeman E W. Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symptoms. Psychoneuroendocrinology 1995; 20: 259–67
   PubMed Web of Science ®Google Scholar
• Hammarbäck S, Bäckström T, Hoist J, et al. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement treatment. Acta Obstet Gynecol Scand 1985; 64: 393–7
   PubMed Web of Science ®Google Scholar
• Magos A L, Brewster E, Sing R, et al. The effect of norethisterone in postmenopausal women on oestrogen therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol 1986; 93: 1290–6
   PubMedGoogle Scholar
• Freeman E W, Rickels K, Sondheimer S J, et al. A double-blind trial of oral progesterone, alprazolam and placebo in treatment of severe premenstrual syndrome. JAMA 1995; 274: 51–7
   PubMed Web of Science ®Google Scholar
• Rubinow D R, Hoban M C, Grover G N, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol 1988; 158: 5–11
   PubMed Web of Science ®Google Scholar
• Bäckström T, Aakvaag A. Plasma prolactin and testosterone during the luteal phase in women with premenstrual tension. Psychneuroendocrinology 1981; 6: 245–51
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Genazzani A D, Martignoni E, et al. Neuroendocrine changes in luteal function in patients with premenstrual syndrome. J Clin Endocrinol Metab 1993; 76: 1123–7
   PubMed Web of Science ®Google Scholar
• Eriksson E, Sundblad C, Lisjö P, et al. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinology 1992; 17: 195–204
   PubMed Web of Science ®Google Scholar
• Hammarbäck S, Damber J-E, Bäckström T. Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J Clin Endocrinol Metab 1989; 68: 125–30
   PubMed Web of Science ®Google Scholar
• Seippel L, Bäckström T. Luteal phase estradiol relates to symptom severity between patients with premenstrual syndrome. J Clin Endocrinol Metab 1998; 83: 1988–92
   PubMed Web of Science ®Google Scholar
• Dhar V, Murphy B E. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology 1990; 15: 489–93
   PubMed Web of Science ®Google Scholar
• Klaiber E L, Broverman D M, Vogel W, et al. Relationships of serum estradiol levels, menopausal duration and mood during hormonal replacement therapy. Psychoneuroendocrinology 1997; 22: 549–58
   PubMed Web of Science ®Google Scholar
• Chan A F, Mortola J F, Wood S H, et al. Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet Gynecol 1994; 84: 1001–5
   PubMed Web of Science ®Google Scholar
• Schmidt P J, Nieman L K, Grover G N, et al. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med 1991; 324: 1174–9
   PubMed Web of Science ®Google Scholar
• Reame N E, Marshall J C, Kelch R P. Pulsatile LH secretion in women with premenstrual syndrome (PMS): evidence for normal neuroregulation of the menstrual cycle. Psychoneuroendocrinology 1992; 17: 205–13
   PubMed Web of Science ®Google Scholar
• McEwen B, Wooley C S. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol 1994; 29: 431–6
   PubMed Web of Science ®Google Scholar
• Sherwin B B. Estrogen effects on cognition in menopausal women. Neurology 1997; 48: S21–S26
   Web of Science ®Google Scholar
• Hammar M, Lindgren R, Berg G E, et al. Effects of hormonal replacement therapy on the postural balance among postmenopausal women. Obstet Gynecol 1996; 88: 955–60
   PubMed Web of Science ®Google Scholar
• Amandusson Å, Hermansson O, Blomqvist A. Colocalization of oestrogen receptor immuno-reactivity and proenkephalin mRNA expression to neurons in the superficial laminae of the spinal and medullary dorsal horn of rats. Eur J Neurosci 1996; 8: 2440–5
   PubMedGoogle Scholar
• Bäckström T, Zetterlund B, Blom S, et al. Effects of continuous progesterone infusion on the epileptic discharge frequency in women with partial epilepsy. Acta Neurol Scand 1984; 69: 240–8
   PubMed Web of Science ®Google Scholar
• Okhura T, Isse K, Akazawa K, et al. Low-dose estrogen replacement therapy for Alzheimer disease in women. Menopause 1994; 1: 125–30
   Web of Science ®Google Scholar
• Majewska M D, Harrison N L, Schwartz R D, et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986; 232: 1004–7
   PubMed Web of Science ®Google Scholar
• Rang H P, Dale M M, Ritter J M. Pharmacology. Churchill Livingstone, Edinburgh 1995; 512–61
   Google Scholar
• Norberg L, Wahlström G, Bäckström T. The anaesthetic potency of 3α-hydroxy-5α-pregnan-20-one and 3α-hydroxy-5β-pregnan-20-one determined with an intravenous EEG-threshold method in male rats. Pharmacol Toxicol 1987; 61: 42–7
   PubMedGoogle Scholar
• Korkmaz SWG. The EEG burst suppression threshold test for the determination of CNS sensitivity to intravenous anaesthetics in rats. Brain Res Protocols 1997; 1: 378–84
   PubMedGoogle Scholar
• Paul S M, Purdy R H. Neuroactive steroids. FASEB J 1992; 6: 2311–22
   PubMed Web of Science ®Google Scholar
• Puia G, Santi M, Vicini S, et al. Neurosteroids act on recombinant human GABAA receptors. Neuron 1990; 4: 759–65
   PubMed Web of Science ®Google Scholar
• Lan N C, Gee K W, Bolger M B, et al. Differential responses of expressed recombinant human γ-aminobutyric acid A receptors to neurosteroids. J Neurochem 1991; 57: 1818–21
   PubMed Web of Science ®Google Scholar
• Karavolas H J, Bertics P J, Hodges D, . Progesterone processing by neuroendocrine structures. Metabolism of Hormonal Steroids in the Neuroendocrine Structures, F Celotti, et al. Raven Press, New York 1984; 149–70
   Google Scholar
• McLcangi R C, Celotti F, Ballabio M, et al. 5β-reductase activity in isolated and cultured neuronal and glial cells of the rat. Brain Res 1990; 516: 229–36
   PubMed Web of Science ®Google Scholar
• Barnea A, Hajibeigi A, Trant J M, et al. Expression of steroid metabolizing enzymes by aggregating fetal brain cells in culture: a model for developmental regulation of the progesterone 5α-reductase pathway. Endocrinology 1990; 127: 500–2
   PubMed Web of Science ®Google Scholar
• Baulieu E E. Steroid hormones in the brain: several mechanisms?. Steroid Hormone Regulation of the Brain, K Fuxe, JA Gustavssob, L Wetterberg. Pergamon Press, Oxford 1981; 3–14, Wennergren Center International Symposium series
   Google Scholar
• Wang M D, Seippel L, Purdy R H, et al. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5α-pregnan-3,20-dione and 3α-hydroxy-5 α-pregnan-20-one. J Clin Endocrinol Metab 1996; 81: 1076–82
   PubMed Web of Science ®Google Scholar
• Backström T, Andersson A, Baird D T, et al. The human corpus luteum secretes 5α-pregnan-3,20-dione. Acta Endocrinol (Copenh) 1986; 111: 116–21
   PubMedGoogle Scholar
• Bixo M, Andersson A, Winblad B, et al. Progesterone, 5-alpha-pregnane-3,20-dione and 3-alpha-hydroxy-5-alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res 1997; 764: 173–8
   PubMed Web of Science ®Google Scholar
• Bitran D, Purdy R H, Kellogg C K. Anxiolytic effect of progesterone is associated with increases in cortical allopregnanolone and GABAA receptor function. Pharmacol Biochem Behav 1993; 45: 423–8
   PubMed Web of Science ®Google Scholar
• Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA-receptors. J Neuroendocrinal 1995; 7: 171–7
   PubMed Web of Science ®Google Scholar
• Wieland S, Lan N C, Mirasedeghi S, et al. Anxiolytic activity of the progesterone metabolite 5β-pregnan-3α-ol-20-one. Brain Res. 1991; 565: 263–8
   PubMed Web of Science ®Google Scholar
• Carl P, Högskilde S, Nielsen J W, et al. Pregnanolone emulsion. A preliminary pharmacokinetic and pharmacodynamic study of a new intravenous anaesthetic agent. Anaesthesia 1990; 45: 189–97
   PubMed Web of Science ®Google Scholar
• Landgren S, Aasly J, Bäckström T, et al. The effect of progesterone and its metabolites on the interictal epileptiform discharge in the cat's cerebral cortex. Acta Physiol Scand 1987; 131: 33–42
   PubMedGoogle Scholar
• Devaud L L, Purdy R H, Morrow A L. The neurosteroid 3α-hydroxy-5α-pregnan-20-one, protects against bicuculline-induced seizures during ethanol withdrawal in rats. Alcohol Clin Exp Res 1995; 19: 350–5
   PubMed Web of Science ®Google Scholar
• Purdy R H, Morrow A L, Moore P H, et al. Stress-induced elevations of the γ-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 1991; 88: 4553–7
   PubMed Web of Science ®Google Scholar
• Patchev V K, Shoaib M, Holsboer F, et al. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience 1994; 62: 265–71
   PubMed Web of Science ®Google Scholar
• Patchev V K, Hassan AHS, Holsboer F, et al. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychopharmacology 1996; 15: 533–40
   PubMed Web of Science ®Google Scholar
• Barbaccia M L, Roscetti G, Trabucchi M, et al. Time-dependent changes in rat brain neuroactive steroid concentrations and GABAA receptor function after acute stress. Neuroendocrinology 1996; 63: 166–72
   PubMed Web of Science ®Google Scholar
• Schmidt P J, Purdy R H, Moore P H, et al. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994; 79: 1256–60
   PubMed Web of Science ®Google Scholar
• Sundström I, Bäckström T. Patients with premenstrual syndrome have decreased saccadic eye velocity compared to control subjects. Biol Psychiatry 1998; 44: 755–64
   PubMed Web of Science ®Google Scholar
• Rapkin A J, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90: 709–14
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Spencer-Gardner L, Gotts C, et al. Progesterone and the premenstrual syndrome: a double blind crossover trial. Br Med J 1985; 290: 1617–21
   PubMed Web of Science ®Google Scholar
• Vanselow W, Dennerstein L, Greenwood K M, et al. Effect of progesterone and its 5α- and 5β-metabolites on symptoms of premenstrual syndrome according to route of administration. J Psychosom Obstet Gynaecol 1996; 17: 29–38
   PubMed Web of Science ®Google Scholar
• Freeman E W, Purdy R H, Coutifaris C, et al. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology 1993; 58: 478–84
   PubMed Web of Science ®Google Scholar
• de Lignieres B, Dennerstein L, Bäckström T. Influence of route of administration on progesterone metabolism. Maturitas 1995; 21: 251–7
   PubMed Web of Science ®Google Scholar
• Sundström I, Andersson A, Nyberg S, et al. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 1998; 67: 126–38
   PubMed Web of Science ®Google Scholar
• Rodriguez-Sierra J F, Hagley M T, Hendricks S E. Anxiolytic effects of progesterone are sexually dimorphic. Life Sci 1986; 38: 1841–5
   PubMed Web of Science ®Google Scholar
• Woods N F, Lentz M J, Mitchell E S, et al. Arousal and stress response across the menstrual cycle in women with three perimenstrual symptom patterns. Res Nurs Health 1994; 17: 99–110
   PubMed Web of Science ®Google Scholar
• Schmidt P J, Grover G N, Hoban M C, et al. State-dependent alterations in the perception of life events in menstrual-related mood disorders. Am J Psychiatry 1990; 147: 230–4
   PubMed Web of Science ®Google Scholar
• Brown M A, Lewis L L. Cycle-phase changes in perceived stress in women with varying levels of premenstrual symptomatology. Res Nurs Health 1993; 16: 423–9
   PubMed Web of Science ®Google Scholar
• Fontana A M, Palfai T G. Psychosocial factors in premenstrual dysphoria: stressors, appraisal, and coping processes. J Psychosomatic Res 1994; 38: 557–67
   PubMed Web of Science ®Google Scholar
• Dickson-Parnell B, Zeichner A. The premenstrual syndrome: psychophysiologic concomitants of perceived stress and low back pain. Pain 1988; 34: 161–9
   PubMed Web of Science ®Google Scholar
• Bäckström T, Smith S, Lothian H, et al. Prolonged follicular phase and depressed gonadotropins following hysterectomy and corpus lutectomy in women with premenstrual tension syndrome. Clin Endocrinol 1985; 22: 723–32
   PubMed Web of Science ®Google Scholar
• Drugan R C, Morrow A L, Weizman R, et al. Stress-induced behavioral depression in the rat is associated with a decrease in GABA receptor-mediated chloride ion flux and brain benzodiazepine receptor occupancy. Brain Res 1989; 487: 45–51
   PubMed Web of Science ®Google Scholar
• Montpied P, Weizman A, Weizman R, et al. Repeated swim-stress reduces GABAA receptor alpha subunit mRNAs in the mouse hippocampus. Brain Res Molec Brain Res 1993; 18: 267–72
   PubMedGoogle Scholar
• Speroff L, Glass R H, Kase N G. Menstrual disorders. Clinical Gynecologic Endocrinology and Infertility 5th edn. Williams and Wilkins, Baltimore, MD 1994; 515–30
   Google Scholar
• Spigset O. The Selective Serotonin Reuptake Inhibitor Fluvoxamine: Aspects on Pharmacokinetics, Pharmacodynamics and Adverse Effects in Healthy Volunteers. 1997; 11–27, Umeå: Umeå University Medical Dissertations, series no. 498
   Google Scholar
• Menkes D B, Coates D C, Fawcett J P. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 1994; 32: 37–44
   PubMed Web of Science ®Google Scholar
• Su T P, Schmidt P J, Danaceau M, et al. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 1997; 82: 1220–8
   PubMed Web of Science ®Google Scholar
• Brzezinski A A, Wurtman J J, Wurtman R J, et al. Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet Gynecol 1990; 76: 296–301
   PubMed Web of Science ®Google Scholar
• Bancroft J, Cook A, Davidson D, et al. Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change. Psychol Med 1991; 21: 305–312
   PubMed Web of Science ®Google Scholar
• Veeninga A T, Westenberg HMG. Serotonergic function and late luteal phase dysphoric disorder. Psychopharmacology 1992; 108: 153–8
   PubMed Web of Science ®Google Scholar
• Fitz-Gerald M, Malone K M, Li S, et al. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. Am J Psychiatry 1997; 154: 556–8
   PubMed Web of Science ®Google Scholar
• Bancroft J, Cook A. The neuroendocrine response to d-fenfluramine in women with premenstrual depression. J Affect Disord 1995; 36: 57–64
   PubMed Web of Science ®Google Scholar
• Halbreich U, Tworek H. Altered serotonergic activity in women with dysphoric premenstrual syndromes. Int J Psychiatry Med 1993; 23: 1–27
   PubMed Web of Science ®Google Scholar
• Eriksson E, Alling C, Andersch B, et al. Cerebrospinal fluid levels of monoamine metabolites. A preliminary study of their relation to menstrual cycle phase, sex steroids, and pituitary hormones in healthy women and in women with premenstrual syndrome. Neuropsychopharmacology 1994; 11: 201–13
   PubMed Web of Science ®Google Scholar
• Rapkin A J, Edelmuth E, Chang L C, et al. Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol 1987; 70: 533–7
   PubMed Web of Science ®Google Scholar
• Rapkin A J, Reading A E, Woo S, et al. Tryptophan and neutral amino acids in premenstrual syndrome. Am J Obstet Gynecol 1991; 165: 1830–3
   PubMed Web of Science ®Google Scholar
• Hallman J, Oreland L, Edman G, et al. Thrombocyte monoamine oxidase activity and personality traits in women with severe premenstrual syndrome. Acta Psychiatr Scand 1987; 76: 225–34
   PubMed Web of Science ®Google Scholar
• Eriksson E, Hedberg M A, Andersch B, et al. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995; 12: 167–76
   PubMed Web of Science ®Google Scholar
• Rickels K, Freeman E W, Sondheimer S, et al. Fluoxetine in the treatment of premenstrual syndrome. Curr Ther Res 1990; 48: 161–6
   Web of Science ®Google Scholar
• Stone A B, Pearlstein T B, Brown W A. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1991; 52: 290–3
   PubMed Web of Science ®Google Scholar
• Menkes D B, Taghavi E, Mason P A, et al. Fluoxetine's spectrum of action in premenstrual syndrome. Int Clin Psychopharmacol 1993; 8: 95–102
   PubMed Web of Science ®Google Scholar
• Sundblad C, Hedberg M A, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: A placebo-controlled trial. Neuropsychopharmacology 1993; 9: 133–45
   PubMed Web of Science ®Google Scholar
• Pearlstein T B, Stone A B. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1994; 55: 332–5
   PubMed Web of Science ®Google Scholar
• Biegon A. Effects of steroid hormones on the serotonergic system. Ann NY Acad Sci 1990; 600: 427–34
   PubMed Web of Science ®Google Scholar
• Ladisich W. Influence of progesterone on serotonin metabolism: a possible causal factor for mood changes. Psychoneuroendocrinology 1977; 2: 257–66
   PubMed Web of Science ®Google Scholar
• Walker R F, Wilson C A. Changes in hypothalamic serotonin associated with amplification of LH-surges by progesterone in rats. Neuroendocrinology 1983; 37: 200–5
   PubMed Web of Science ®Google Scholar
• Rakoff J S, Rigg L A, Yen SSC. The impairment of progesterone-induced pituitary release of prolactin and gonadotropin in patients with hypothalamic chronic anovulation. Am J Obstet Gynecol 1978; 130: 807–12
   PubMed Web of Science ®Google Scholar
• Bethea C. Colocalization of progestin receptors with serotonin in raphe neurons of macaque. Neuroendocrinology 1993; 57: 1–6
   PubMed Web of Science ®Google Scholar
• Gonzales G F, Carrilo C. Blood serotonin levels in postmenopausal women: effects of age and serum oestradiol levels. Maturitas 1993; 17: 23–9
   PubMed Web of Science ®Google Scholar
• Mueck A O, Seeger H, Kasspohl-Butz S, et al. Influence of norethisterone acetate and estradiol on the serotonin metabolism of postmenopausal women. Horn Metab Res 1997; 29: 80–3
   PubMed Web of Science ®Google Scholar
• Lippert T H, Filshie M, Mueck A O, et al. Serotonin metabolite excretion after postmenopausal estradiol therapy. Maturitas 1996; 24: 37–41
   PubMed Web of Science ®Google Scholar
• Halbreich U, Rojansky N, Palter S, et al. Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry 1995; 37: 434–41
   PubMed Web of Science ®Google Scholar
• O'Keane V, O'Hanlon M, Webb M, et al. d-fenfluramine/prolactin response throughout the menstrual cycle: evidence for an oestrogen-induced alteration. Clin Endocrinol (Oxf) 1991; 34: 289–92
   PubMed Web of Science ®Google Scholar
• Eyal S, Weizman A, Toren P, et al. Chronic GnRH agonist administration down-regulates platelet serotonin transporter in women undergoing assisted reproductive treatment. Psycho-pharmacology 1996; 125: 141–5
   PubMed Web of Science ®Google Scholar
• Sundström I, Bäckström T. Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. Psychoneuroendocrinology 1998; 23: 73–88
   PubMed Web of Science ®Google Scholar
• Uzonov D P, Cheney C L, Costa E, et al. Fluoxetine treatment selectively causes brain accumulation of allopregnanolone in rats. Proc Natl Acad Sci USA 1996; 93: 12599–604
   PubMedGoogle Scholar
• Romeo E, Strohle A, Spaletta G, et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatr 1998; 155: 910–3
   PubMed Web of Science ®Google Scholar
• Parry B L, Gerner R H, Wilkins J N, et al. CSF and endocrine studies of premenstrual syndrome. Neuropsychopharmacology 1991; 5: 127–37
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Romano G, Fava M, et al. Lactate infusion induces panic attacks in patients with premenstrual syndrome. Psychosom Med 1992; 54: 288–96
   PubMed Web of Science ®Google Scholar
• Harrison W M, Endicott J, Rabkin J G, et al. Treatment of premenstrual dysphoria with alprazolam and placebo. Psychopharmacol Bull. 1987; 23: 150–3
   PubMedGoogle Scholar
• Smith S, Rinehart J S, Ruddock V E, et al. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 1987; 70: 37–43
   PubMed Web of Science ®Google Scholar
• Hommer D W, Matsuo V, Wolkowitz O, et al. Benzodiazepine sensitivity in normal human subjects. Arch Gen Psychiatry 1986; 43: 542–51
   PubMed Web of Science ®Google Scholar
• Sundström I, Ashbrook D, Bäckström T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 1997; 22: 25–38
   PubMed Web of Science ®Google Scholar
• Sundström I, Nyberg S, Bäckström T. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 1997; 17: 370–81
   PubMed Web of Science ®Google Scholar
• Roy-Burne P P, Cowley D S, Greenblatt D J, et al. Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 1990; 47: 534–8
   PubMed Web of Science ®Google Scholar
• Glue P. The pharmacology of saccadic eye movements. J Psychopharmacol 1991; 5: 377–87
   PubMedGoogle Scholar
• Barnes EM, Jr. Use-dependent regulation of GABAA receptors. Int Rep Neurobiol 1996; 39: 53–76
   PubMed Web of Science ®Google Scholar
• Miller L G, Greenblatt D J, Barnhill J G, et al. Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased gamma-aminobutyric acid A receptor function. J Pharmacol Exp Therapeut 1988; 246: 170–6
   PubMed Web of Science ®Google Scholar
• Yu R, Hay M, Ticku M K. Chronic neurosteroid treatment attenuates single cell GABAA response and its potentiation by modulators in cortical neurons. Brain Res 1996; 706: 160–2
   PubMed Web of Science ®Google Scholar
• Friedman L, Gibbs T T, Farb D H. Gamma-aminobutyric acid A receptor regulation: chronic treatment with pregnanolone uncouples allosteric interactions between steroid and benzodiazepine recognition sites. Mol Pharmacol 1993; 44: 191–7
   PubMed Web of Science ®Google Scholar
• Weiland N G, Orchinik M. Specific subunit mRNAs of the GABAA receptor are regulated by progesterone in subfields of the hippocampus. Brain Res Molec Brain Res 1995; 32: 271–8
   PubMedGoogle Scholar
• Orchinik M, Weiland M, McEwen NGBS. Chronic exposure to stress levels of corticosterone alters GABAA receptor subunit mRNA levels in rat hippocampus. Brain Res Molec Brain Res 1995; 34: 29–37
   PubMedGoogle Scholar
• Gallo M A, Smith S S. Progesterone withdrawal decreases latency to and increases duration of electrified prod burial: a possible rat model of PMS anxiety. Pharmacol Biochem Behavior 1993; 46: 897–904
   PubMed Web of Science ®Google Scholar
• Smith S S, Gong Q H, Hsu F C, et al. GABA(A) receptor alpha-4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998; 392: 926–30
   PubMed Web of Science ®Google Scholar